Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach

Jennifer Rozylo1, Keren Mitchell1,2,3, Mohammadali Nikoo1,4, S. Elise Durante2,3, Skye P. Barbić1,2,3,5,7,8, Daniel Lin1,2,3, Steve Mathias1,2,3,7 and Pouya Azar1,2,3,5,6*

Abstract

Background: The requirement for moderate withdrawal prior to initiation can be a barrier to buprenorphine/naloxone induction.

Case presentation: We aimed to use a microdosing regimen to initiate regular dosing of buprenorphine/naloxone in a high-risk patient with a history of failed initiations due, in part, to withdrawal symptoms. Using an assertive outreach model and a buprenorphine/naloxone microdosing schedule, we initiated treatment of an individual's opioid use disorder. There was a successful buprenorphine/naloxone microdosing induction as the team reached a therapeutic dose of buprenorphine/naloxone. Including the induction period, the medication was used consistently for 4 weeks.

Conclusions: A microdosing schedule can be used to induce a patient onto buprenorphine/naloxone with no apparent withdrawal; gradually reducing illicit substance use. This case report builds on previous literature, highlighting ways to minimize barriers to induction of buprenorphine/naloxone, using a microdosing schedule and assertive outreach. Given the safety profile of buprenorphine and its potential to be a lifesaving intervention, a larger study of microdosing is indicated.

Keywords: Opioid use disorder, Buprenorphine/naloxone, Microdosing, Bernese method, Induction method

Background

Over the past 10 years, rates of opioid-related overdose deaths and opioid-related harms have drastically increased in British Columbia [1]. Since 2015, illicit drug use has surpassed suicide as the major cause of unnatural deaths in BC, with fentanyl-related overdoses implicated as the leading cause of illicit drug overdoses [1]. This public health crisis of historical scale has taken more lives than the HIV epidemic in the early 1990’s [2]. The latter at its peak (1995) was identified as the cause of a total of 1764 mortalities in Canada [3] compared to 4588 reported apparent opioid-related deaths in Canada in 2018 [4] when, approximately four people lost their lives to overdose every day in BC [1].

Opioid agonist treatment (OAT) has been shown to reduce morbidity and mortality among patients with opioid use disorder (OUD) [5–10]. Buprenorphine/naloxone has become the recommended first-line OAT in Canada based on its preferable safety profile and efficacy [11, 12].

Buprenorphine is a partial μ agonist, with high receptor affinity resulting in a slow dissociation from the receptor and prolonged activity. Naloxone has minimal effect when taken orally and is introduced to the formula to minimize diversion. The pharmacokinetics of buprenorphine/naloxone result in a favourable safety profile due to...
The Pharmacological hypothesis tested in the Bernese Method is that small amounts of buprenorphine doses should not precipitate opioid withdrawal, but because of its relatively long half-life, accumulates at the receptor gradually replacing the full μ-agonist (e.g. fentanyl, heroin) at the opioid receptor. This was successfully shown with these two cases presented by Hamming; however, this has not been replicated in the current practice literature [16, 17].

There has been growing interest in the Bernese Method in Vancouver, BC, Canada, as healthcare providers struggle to find ways to reduce mortality in the context of a public health emergency. To date, there has been considerable effort to engage individuals who use opioids in opioid agonist treatment, as well as to provide overdose response kits and personnel to manage acute overdoses [18]. The Bernese Method is a potential compliment to patients who want treatment with buprenorphine/naloxone, but are adverse to the traditional induction method because of the need for withdrawal and/or have difficulty attending scheduled appointments. This method has also shown promise for other indications such as pain management [19].

Apart from above-mentioned barriers, there remains other challenges for home induction with BUP/NLX. Home induction works best for patients who have stable housing, relatively good cognitive function, and are organized enough to reliably follow instructions. Unfortunately, this is not the case for most of patients who are served by the outreach programs, patients with severe opioid use disorder, high rates of cognitive impairment and major mental health illness in the most vulnerable opioid using population i.e. homeless population that can interfere with their ability to come to a clinic, tolerate withdrawal, and stay for induction and as a result precludes them often from successful home induction. Provision of microdosing within an outreach program can make buprenorphine/naloxone treatment accessible to high-risk patients who have difficulty attending office-based appointments or complying with a home-based protocol. Assertive outreach, part of this model of care, involves flexible delivery of integrated health services by an interdisciplinary team and is an established model for engaging patients with complex needs that have not been met in traditional office-based settings [20, 21]. The Inner City Youth Program (ICYP) uses this approach with high-risk youth who are living with moderate to severe mental illness and/or substance use disorders, and psychosocial and/or medical complexities. The ICYP is located at Findory Vancouver Granville, which is a “one-stop shop” health centre in downtown Vancouver for young people aged 12–24, which includes support to family members and caregivers. Care is provided by an interdisciplinary
team of peers and professionals through clinic-based and outreach services.

In February 2018, we began using a microdosing regimen to initiate regular dosing of buprenorphine/naloxone in ICYP patients with significant barriers to induction, such as developmental disabilities, homelessness, and psychosis. We used assertive outreach to identify and locate patients with OUD who were not receiving OAT and offer them buprenorphine/naloxone microdosing induction on the spot. OAT prescribers offered weekly outreach, and interdisciplinary team members provided case management and supported patients with their OAT and other related goals. Patients were linked to primary care, psychiatry, peer support and other services.

In the first 6 months of this program, 14 people, 18–25 years-old with severe disordered use of multiple substances and comorbid mental illness, and history of residential instability and poverty were engaged in care with 8 successful inductions and no instances of precipitated withdrawal. This method has also attracted growing interest among other clinics in our community. As there are limited published reports on this topic, we present a case report for discussion to contribute to the body of evidence. Specifically, we present a case of a patient successfully completing buprenorphine/naloxone induction, without reporting a period of withdrawal, using a microdosing schedule delivered via assertive outreach. Success was defined as reaching a therapeutic dose of Suboxone for a minimum of 30 consecutive days.

Case presentation
The patient was a 55-year-old male, a parent of one of our youth outreach patients. He reported being First Nations, living in a single-room-occupancy hotel, and supported by income assistance. He had a long history of opioid and stimulant use disorders. Given the incredible urgency and need for flexibly service delivery in the context of OAT, he was taken as a patient in our youth outreach program to help family members in innovative ways. His presentation was complicated by an evolving left leg cellulitis, untreated hepatitis C, and a history of gout. At the time of initial assessment, he was not taking any medications. Our team was consulted to see him for buprenorphine/naloxone microdosing induction in his residence. Visiting the patient in his residence was used as a measure to lower the threshold for access to care and improve his engagement with the treatment.

On initial assessment, the patient self-reported injecting 200 mg of heroin daily 200 mg of crystal methamphetamine every 3 days. The actual amounts used was difficult to measure given the variability in chemical make-up and potency of heroin and other street drugs in Vancouver, including their adulteration with fentanyl and other contaminants [22, 23].

The patient had previously trialed methadone but had relapsed. He had multiple trials of traditional buprenorphine/naloxone inductions but was unable to complete them due to his intolerance of withdrawal symptoms. He had experienced at least one overdose requiring resuscitation with naloxone.

Outreach visits to this patient began February 28, 2018 and he was seen four times (out of five attempted visits) over 3 weeks at his residence. The patient was prescribed a buprenorphine/naloxone microdosing regimen (see Fig. 1). The BUP/NLX tablets were split by the local pharmacy for off-label administration of small doses in microdosing protocol. Since the smallest available dose in Canada is 2 mg, it was more practical to split the tablets into 0.25 mg as opposed to 0.2 mg, which was prescribed in Bernese Method. The patient was instructed to use decreasing doses of heroin as buprenorphine/naloxone doses increased, then to stop heroin once the buprenorphine dose reached 12 mg. He completed the microdosing regimen and over the course of 7 days his dose was titrated to 12 mg daily. On day 8 the dose was increased to 16 mg daily and the patient abstained from illicit drugs. Despite the team offering to deliver the medication to the patient’s home, he chose to pick them up himself daily from the pharmacy. The outreach team supported him with reminders to pick up his medications regularly. Due to a prescription error, he missed 3 days of his buprenorphine/naloxone (March 20–23, 2018), and a relapse of heroin and crystal methamphetamine ensued. A subsequent retrial of buprenorphine/naloxone microdosing induction was prescribed, but the patient did not pick up his medications, and was difficult to find for follow up.

The patient was seen again on outreach visits to his residence and neighbourhood starting on May 14, 2018. He was contemplative about quitting heroin. He wanted to retries the microdosing induction method. We conducted a medical history, screening for major health concerns, liver failure, other medications and allergies. Blood work from December 2017 showed normal complete blood count, electrolytes, blood urea nitrogen, and creatinine. December 2016 liver function tests were normal. A microdosing buprenorphine/naloxone regimen was re-prescribed, along with a blood requisition for updated liver function tests, human immunodeficiency virus, treponema pallidum, hepatitis B virus, complete blood count, electrolytes, blood urea nitrogen, and creatinine. Medication was dispensed daily to the patient at a pharmacy situated across the street from his residence. The prescriber and the pharmacy stayed in close phone and
in-person connection regarding dosage adjustments and medication adherence.

The patient picked up and took all but two doses in the first week. There were no symptoms of withdrawal throughout the induction. This was documented via the patients self-report and the clinicians' overall assessment of the patient's withdrawal symptoms as the use of standardized tools was neither feasible nor necessary given that withdrawal prior to induction is not a requirement in microdosing technique. The patient reduced illicit heroin use to 200 mg every 2 days during the week of the microdosing. The patient had mild cravings when he reached 12 mg, though decreased his use to 100 mg every three days. Follow up was challenging because the patient had difficulty keeping appointments, and we were not always able to locate him on outreach. The team looked for the patient in his home and in the neighborhood, and after several attempts assessed him on May 28, 2018. At the time, he was on 12 mg daily. He continued to self-report using heroin 500 mg every 3 days, and experiencing cravings, so his dose was increased to 16 mg. He continued to stay on buprenorphine/naloxone 16 mg daily, with no missed doses.

He was assessed again on June 11, 2018. Notably, a painful left leg cellulitis persisted, and he continued to use heroin 500 mg every 3 days when he felt leg pain. While he reported mild cravings, he reported using heroin to manage pain. The team connected him to a nearby primary care clinic for wound care and antibiotics. The dose of buprenorphine/naloxone was increased to 20 mg daily. He adhered to his agonist medication till August 27, 2018 and reported using 50 mg approximately every 4 days, which he was willing to taper. Interestingly, he reported no longer using any other illicit substances. The outreach team supported him to connect with an adult-oriented primary care and OAT clinic, and his care was transferred accordingly.

Discussion and conclusions

We presented a case of an induction to buprenorphine/naloxone using a microdosing schedule (Bernese Method) with no apparent withdrawal. The induction was conducted successfully as part of the outreach visits to the patient’s residence in a single-room-occupancy hotel in downtown Vancouver. The outreach component, which sets this apart from the Bernese Method alone, aimed to promote adherence and minimize barriers for patients with multiple treatment failures and complex medical comorbidities. The combination of buprenorphine/naloxone safety profile, and flexible microdosing schedule are well suited to the outreach model and a complex patient population. Further studies could study the effectiveness of microdosing as compared to outreach component towards the effectiveness of the overall model for instance by comparing patients receiving...
outreach intervention with microdosing induction or regular buprenorphine dose induction. However such a study will be very challenging because traditional induction methods have been limited in their utility due to the profound executive dysfunction in this population. They are migratory and difficult to locate. They are impulsive in their substance use and struggle so much with their organization and planning that traditional induction methods are for the most part impractical. The flexibility that microdosing affords in the real-world allows induction to occur in a much more resource-efficient and achievable way.

This report shows that a microdosing schedule can be used to induce a patient onto buprenorphine/naloxone, with no apparent withdrawal, and reduced illicit substance use. Secondary benefits included increased connection with the healthcare team, and treatment of the patient’s cellulitis.

Further carefully designed research is needed to build evidence regarding the viability and efficacy of the Bernese Method in an outreach setting. The optimum dosing schedule has yet to be defined. A major limitation of this method is the continued illicit opiate use during the initial phases of the induction. The OAT may reduce or stop opioid use, but that is not the only rationale for it. Harm reduction is a pragmatic approach which focuses on immediacy of needs, patient-chosen goals, and on reducing the harms. Individuals with opioid use disorder are at extraordinarily high risk of mortality and morbidity. Opioid agonist therapy can lead to reduced opioid use, but it is also an evidence-based harm-reduction treatment in individuals who are continuing to use opioids. These include a reduction in overdoses, infectious diseases, legal problems, hospitalization and a greater stability and engagement in mental and physical health services. In addition, as in this case, usual induction is not an option for some patients and microdosing technique within the outreach program provides an alternative to ongoing use and not engaging with any sort of treatment. Hence, offering microdosing despite continued use in such cases can be considered a pragmatic harm reduction approach and may even decrease the overall risk of overdose by focussing on patients’ chosen goals and immediacy of their needs, engaging them with the treatment, and addressing often multiple concurrent illnesses such as hepatitis C, HIV, and psychosis. These yet need to be evaluated in further studies.” Also, given the high initial attrition rate of buprenorphine maintenance treatment ranging between 10 and 24% [24–26] in the first week, it is critical that novel and innovative approaches are used to overcome obstacles to initiation, e.g. requirement for withdrawal prior to induction. The Bernese Method delivered by an outreach team is a promising alternative to overcomes this obstacle while minimizing the risk for overdoses at a critical and vulnerable time. Another limitation is missing standard measurements of withdrawal and urine drug screen for illicit drug use, as the withdrawal was assessed by clinician impression and patient self-report. This could be partly explained by less than ideal setting of an outreach visit requiring optimal use of the time in a short encounter. Such measures would have allowed for a full evaluation and comparison with existing described methods. Also, the splitting of BUN/NLX tablets might not have been 100% accurate in this study; however, it was effective in that the premise is to start low and gradually increase. Best practice for dosing has yet to be established and dosing accuracy would need to be assured for future studies. Further research needs to explore feasibility of the Bernese Method in an outreach setting with a larger group of patients and warrants a comparison of the protocol versus current best practice. Further study is also needed to clarify which interventions may have assisted this patient to discontinue methamphetamine use as part of this intervention.

This case report explores a novel way to minimize barriers to induction of first-line opioid agonist treatment in Canada, buprenorphine/naloxone, by eliminating withdrawal symptoms in this phase, using a microdosing regimen based on the Bernese Method, provided as part of an outreach program.

**Abbreviations**

OAT: opioid agonist treatment; OUD: opioid use disorder; ICY: Inner City Youth Program; ICM: intensive case management.

**Acknowledgements**

We would like to acknowledge and thank the team at the Inner City Youth Program, Foundry Vancouver—Granville (https://foundrybc.ca/) who made this research possible by allocating space and staffing resources to this project. MN is supported by Frederick Banting and Charles Best Canada Graduate Scholarships (Funding Reference Number = 157934).
Consent for publication
No personal identifier is included.

Competing interests
The authors report no potential conflicts of interest. The authors alone are responsible for the content and writing of this paper.

Author details
1 University of British Columbia, Vancouver, BC, Canada. 2 Inner City Youth Program, Providence Health Care, Vancouver, BC, Canada. 3 Foundry, Providence Health Care, Vancouver, BC, Canada. 4 Addiction and Concurrent Disorders Group, Institute of Mental Health, University of British Columbia, Vancouver, BC, Canada. 5 St Paul's Hospital, Vancouver, BC, Canada. 6 Vancouver General Hospital, DHCC, Floor 8-2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada. 7 Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada. 8 Department of Occupational Science and Occupational Therapy, University of British Columbia, Vancouver, BC, Canada.

Received: 11 June 2019  Accepted: 4 January 2020
Published online: 15 January 2020

References
1. British Columbia Coroners Service. Illicit drug overdose deaths in BC January 1, 2008–January 31, 2018, 2018.
2. Global Commission on Drug Policy. The opioid crisis in North America; 2017.
3. Government of Canada. Deaths [Internet]. https://www150.statcan.gc.ca/r1/daily-quotidien/990513/dq990513a-eng.htm. Accessed 1 Dec 2019.
4. Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: apparent opioid-related deaths in (released September 2018)—Canada. Ottawa, 2018.
5. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.CD002207.pub4.
6. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009. https://doi.org/10.1002/14651858.CD002209.pub2.
7. Gowing L, Farrell MF, Borneemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane database Syst Rev. 2011,8:CD00145.
8. Nolan S, Hayashi K, Milloy MJ, Kerr T, Dong H, Lima VO, et al. The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting. Drug Alcohol Depend. 2015;156:57–61.
9. Hser Y-I, Evans E, Huang D, Weiss R, Saxorn A, Carroll KM, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016;111(4):695–705.
10. Clausen T, Anchersten K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1–3):151–7.
11. British Columbia Center on Substance Use. A guideline for the clinical management of opioid use disorder; 2017.
12. Bruneau J, Ahamad K, Goyer ME, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorder: a national clinical practice guideline. CMAJ. 2018;190:E247–57.
13. Danuijitaite R, Carlsson R, Bramham G, Cameron D, Sheehy A. Sub is a weird drug: a web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms. Am J Addict. 2015;24:403–9.
14. Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, et al. Patient perspectives on buprenorphine/naloxone: A qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs. 2014;46:412–26.
15. Srivastava A, Kahan M, Leece P, McAndrew A. Buprenorphine unobserved “home” induction: a survey of Ontario’s addiction physicians. Addict Sci Clin Pract. 2019;14:18.
16. Hämmerl R. Einleitung einer Substitutionsbehandlung mit Buprenorphin unter vorübergehender Überlappung mit Heroininkonsum: ein neuer Ansatz (“Berner Methode”) [Induction of a buprenorphine substitution treatment with temporary overlap of heroin use: a new approach (“Berner Method”)]. Suchttherapie. 2010;1:11:29–12 (in German).
17. Hämmerl R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99–105.
18. Government of British Columbia. Overdose prevention and response in B.C. [Internet]. 2019. https://www.stopoverdose.gov.bc.ca/. Accessed 9 Feb 2019.
19. Sandhu R, Zivanovic R, Klaire S, Nikoo M, Rozylo J, Azar P. Buprenorphine/naloxone induction for treatment of acute on chronic pain using a microdosing regimen: a case report. Can J Pain. 2019;3(1):79–84. https://doi.org/10.1080/24740527.2019.1599279.
20. Bond GR, Drake RE. The critical ingredients of assertive community treatment and mortality in people after initial entry to methadone and buprenorphine treatment. World Psychiatry. 2015;14:240–2.
21. Hurley DJ, O’Reilly RL. Resilience, mental health and assertive community treatment. Soc Work Ment Health. 2017;15(6):730–48. https://doi.org/10.1080/15332985.2017.1302038.
22. Jones AA, Jang K, Panenka WJ, Barr AM, MacEwen GW, Thornton AE, et al. Rapid change in fentanyl prevalence in a community-based high-risk sample. JAMA Psychiatry. 2018;75(3):298–300.
23. Department of Justice Canada. Methamphetamine report for federal-provincial-territorial ministers responsible for justice. [Internet]; 2007. https://www.justice.gc.ca/eng/rp-pr/other-autre/meth/p3.html. Accessed 9 Feb 2019.
24. Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104:1193–200.
25. Stein MD, Cloe P, Friedmann PD. Brief report: buprenorphine retention in primary care. J Gen Intern Med. 2005;20:1038–41.
26. Mattick RP, Ali R, White JM, O’Brien S, Wolff S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003;98:441–52.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.